MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
- PMID:9155050
- PMCID: PMC2228229
- DOI: 10.1038/bjc.1997.221
MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
Abstract
MDM2 is an oncoprotein that inhibits p53 tumour-suppressor protein. Amplification of the MDM2 gene and overexpression of its protein have been observed in some human malignancies, and these abnormalities have a role in tumorigenesis through inactivation of p53 function. To determine the clinicopathological and prognostic value of MDM2 abnormalities in non-small-cell lung cancer (NSCLC), MDM2 gene amplification and its protein expression status were analysed in surgically resected materials. MDM2 gene amplification was detected in only 2 (7%) of the 30 tested patients. MDM2 protein was found immunohistochemically in a total of 48 (24%) of the 201 patients. MDM2 protein was slightly frequently observed in patients with adenocarcinoma, but its presence or absence was not associated with clinicopathological factors such as T-factor, N-factor, stage, tumour size, differentiation or p53 protein status. Overall, MDM2-positive patients tended to have a better prognosis (P = 0.062). In particular, among immunohistochemically p53-negative patients (n = 110), those with positive MDM2 protein expression showed significantly better prognosis (P = 0.039) and, in a multivariate analysis, MDM2 protein status was a favourable prognostic factor (P = 0.037). In contrast, among p53-positive patients (n = 91), there was no difference in prognosis depending on MDM2 protein status. Thus, in the NSCLC patients studied, MDM2 gene amplification was a minor event, but expression of its protein, which was often observed immunohistochemically, was a favourable prognostic marker, especially among patients without p53 protein accumulation. Further study is needed to determine how MDM2 protein expression results in a better prognosis.
Similar articles
- MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H.Ko JL, et al.Int J Cancer. 2000 May 20;89(3):265-70. doi: 10.1002/1097-0215(20000520)89:3<265::aid-ijc9>3.0.co;2-n.Int J Cancer. 2000.PMID:10861503
- MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, Jakóbkiewicz-Banecka J, Kobierska-Gulida G, Szymanowska A, Skokowski J, Roessner A, Schneider-Stock R.Dworakowska D, et al.Lung Cancer. 2004 Mar;43(3):285-95. doi: 10.1016/j.lungcan.2003.09.010.Lung Cancer. 2004.PMID:15165086
- The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation.Saito H, Tsujitani S, Oka S, Ikeguchi M, Maeta M, Kaibara N.Saito H, et al.Ann Surg Oncol. 2002 Jun;9(5):450-6. doi: 10.1007/BF02557267.Ann Surg Oncol. 2002.PMID:12052755
- Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S, Solèr M, Stulz P, Mihatsch MJ, Gudat F.Dalquen P, et al.J Pathol. 1996 Jan;178(1):53-8. doi: 10.1002/(SICI)1096-9896(199601)178:1<53::AID-PATH415>3.0.CO;2-T.J Pathol. 1996.PMID:8778317Review.
- Overexpression of the MDM2 oncogene in leukemia and lymphoma.Watanabe T, Ichikawa A, Saito H, Hotta T.Watanabe T, et al.Leuk Lymphoma. 1996 May;21(5-6):391-7, color plates XVI following 5. doi: 10.3109/10428199609093436.Leuk Lymphoma. 1996.PMID:9172803Review.
Cited by
- MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.Ryan BM, Calhoun KM, Pine SR, Bowman ED, Robles AI, Ambs S, Harris CC.Ryan BM, et al.Int J Cancer. 2012 Dec 1;131(11):2710-6. doi: 10.1002/ijc.27573. Epub 2012 Apr 27.Int J Cancer. 2012.PMID:22487911Free PMC article.
- The MDM2 gene amplification database.Momand J, Jung D, Wilczynski S, Niland J.Momand J, et al.Nucleic Acids Res. 1998 Aug 1;26(15):3453-9. doi: 10.1093/nar/26.15.3453.Nucleic Acids Res. 1998.PMID:9671804Free PMC article.Review.
- Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions.Sahu P, Donovan C, Paudel KR, Pickles S, Chimankar V, Kim RY, Horvart JC, Dua K, Ieni A, Nucera F, Bielefeldt-Ohmann H, Mazilli S, Caramori G, Lyons JG, Hansbro PM.Sahu P, et al.Front Oncol. 2023 Sep 25;13:1260411. doi: 10.3389/fonc.2023.1260411. eCollection 2023.Front Oncol. 2023.PMID:37817767Free PMC article.Review.
- Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.Taguchi A, et al.Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.Proteomics. 2014.PMID:25331784Free PMC article.
- mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis.Borzi C, Calzolari L, Centonze G, Milione M, Sozzi G, Fortunato O.Borzi C, et al.Int J Mol Sci. 2017 Jan 23;18(1):222. doi: 10.3390/ijms18010222.Int J Mol Sci. 2017.PMID:28124991Free PMC article.
References
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous